Kahf Biotech

About the offering

KAHF Biotech is a preclinical-stage biotechnology startup developing novel cancer therapeutics targeting metastatic and dormant cancer cells—areas often overlooked in conventional oncology. The company's dual therapeutic strategy aims to block metastasis in early-stage disease and kill tumors in late-stage disease, initially focused on pancreatic ductal adenocarcinoma (PDAC), with a platform approach expandable to multiple solid tumors expressing the same receptor target. The Problem The pitch materials provided are limited, but the company focuses on pancreatic ductal adenocarcinoma (PDAC), one of the deadliest cancers with a five-year survival rate below 12%. Conventional oncology approaches largely overlook metastatic and dormant cancer cells, which are responsible for disease recurrence and progression. PDAC has limited effective treatment options, and most existing therapies target primary tumors rather than the metastatic cascade that ultimately drives patient mortality. The Solution KAHF is developing therapeutics against a novel target in PDAC with limited prior characterization and promising preclinical validation. The company's dual therapeutic strategy addresses two distinct stages of disease: blocking metastasis early in disease progression and killing tumors in late-stage disease. The lead program involves antibody development against a receptor expressed across multiple solid tumor types, creating a platform approach that could expand beyond PDAC. The company highlights that lead antibody development is achievable with approximately $40-50K, positioning this as a capital-efficient development plan relative to typical biotech programs. Business Model As a preclinical-stage biotech, KAHF's path to revenue would follow the standard drug development trajectory: preclinical validation, IND filing, clinical trials, and either regulatory approval for direct commercialization or licensing/acquisition by a larger pharmaceutical company. The platform approach targeting a receptor expressed across multiple solid tumors could generate multiple drug candidates from the same foundational research. Traction The company has promising preclinical validation of its novel target in PDAC. The specific nature and extent of preclinical data (in vitro, in vivo, animal models) was not detailed in the provided materials. No partnerships, grants, or institutional collaborations were disclosed beyond the investor endorsement. Team Founder and CEO Muhammad Sadeqi Nezhad founded KAHF Biotech to pioneer therapeutic strategies targeting metastatic and dormant cancer cells. No additional team members, scientific advisory board, or research collaborators were identified in the provided materials. Featured Investor Syndicate Lead Ronald L. Krall invested $10,000. He is the former Chief Medical Officer of GlaxoSmithKline, former Head of US Development at AstraZeneca, Chairman of the Board of Pierian Biosciences, and Senior Advisor at EIT Pharma. He oversaw the development of more than 20 medicines including multiple anti-cancer drugs during his career. He described KAHF's foundational research as "novel and warrants development investment" and called the investment "potentially transformative," noting the initial target is promising.

FAQ